Dynavax Technologies | DVAX - Cost Of Sales



Dynavax Technologies reported $14.04M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
AbbVie USD 4.35B 344M Jun/2025
Adma Biologics USD 54.76M 544K Jun/2025
Amgen USD 3.01B 406M Jun/2025
AstraZeneca USD 2.47B 232M Jun/2025
Biogen USD 605M 24.3M Jun/2025
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Dynavax Technologies USD 14.04M 13.5M Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
Glaxosmithkline GBP 2.16B 363M Jun/2025
Merck USD 2.82B 53M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
TG Therapeutics USD 18.94M 3.4M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025